Clinical

While multiple machine learning (ML) algorithms offered similar predictive performance, the cost-effective analysis revealed stark differences in the costs associated with their use.

Tear film stability, tear production, ocular surface health, and symptoms were all significantly improved with the use of punctal plugs.

Explore the latest advancements in ovarian cancer treatment, focusing on combination therapies and innovative approaches for platinum-resistant patients.

Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of breath–predominant presentations.

Panelists discuss how preventing bronchiectasis exacerbations involves understanding a patient’s past exacerbation pattern, implementing comprehensive airway clearance, patient education, and early intervention.

Explore the importance of clinical trials for ovarian cancer treatments, highlighting innovative therapies and the need for early patient access.

Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer survival disparities among racial and ethnic subgroups, particularly within disaggregated Asian American, Native Hawaiian, and Pacific Islander populations.

Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay on ALK inhibitor therapy to realize long-term benefits.

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by preventing progression to kidney failure and avoiding the enormous expenses of dialysis and transplantation.

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can significantly reduce long-term costs by delaying progression to advanced kidney disease, preventing complications, and minimizing the need for expensive renal replacement therapies.

Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.

Explore 5 rare genetic and neurological disorders named after pioneering women in medicine, highlighting their significant contributions to previously unknown conditions.

A panelist discusses how HIV treatment has evolved with tremendous improvements in efficacy, tolerability, and convenience, with exciting developments at the Conference on Retroviruses and Opportunistic Infections 2025, including new long-acting therapies for treatment and prevention that could last up to 2 years.

Gerard Criner, MD, FACP, FACCP, MATINEE investigator, highlights trial results that showed reduced exacerbations and delayed disease progression in patients with eosinophilic chronic obstructive pulmonary disease (COPD).

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.

Margrit Wiesendanger, MD, PhD, discusses how lupus treatment is evolving from traditional therapies to more targeted options like biologics, with promising advances now being explored in clinical trials.

Untreated Spinal Muscular Atrophy leads to severe complications and declines in quality of life, emphasizing the need for early intervention.

Early intervention in Spinal Muscular Atrophy is crucial for better outcomes, emphasizing the need for timely treatment to prevent irreversible disability.

Panelists discuss how stakeholders can prepare for the upcoming interchangeability designation of more biosimilars later this year, debating whether interchangeability status or formulary-level changes are more impactful and identifying necessary systemic shifts required to ensure both patients and health systems realize meaningful cost savings when transitioning from reference products to biosimilars.

Panelists discuss how major PBMs' (pharmacy benefit managers) decisions to prefer biosimilars over reference biologics provide valuable insights into successful adoption strategies, specifically examining CVS Caremark's removal of reference biologic adalimumab from national commercial template formularies, which resulted in 97% of prescriptions being filled with preferred biosimilars, and analyzing the key implementation factors driving this remarkable conversion rate.

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

Minimally invasive glaucoma surgery offers alternatives for patients looking for methods of treating glaucoma without affecting quality of life.

Panelists discuss how ideal candidates for bronchiectasis surgery have localized disease on CT scan and bronchoscopy, adequate pulmonary function (orced expiratory volume in 1 second > 40%), and whose infections are controlled prior to surgery.

Panelists discuss how reducing bronchiectasis exacerbations requires standardized definitions, tailored antibiotic approaches, and increased airway clearance, while addressing underlying conditions and ongoing research into optimal treatment protocols.

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers.

Innovative antibody drug conjugates are advancing in ovarian cancer treatment, exploring new maintenance therapies and biomarker-driven approaches for improved outcomes.

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

Panelists discuss how immunoglobulin A (IgA) nephropathy progression creates escalating economic burdens for patients through direct health care costs, lost productivity, increasing medication needs, and eventually the overwhelming financial impact of dialysis or transplantation.

Panelists discuss how ALK inhibitors compare in terms of tolerability and best practices for managing associated toxicities.